Leadership

Carl LeBel, PhD

Chief Development Officer

Carl has been the Chief Development Officer at Frequency since 2018. He started LeBel Consulting LLC after serving as the Chief Scientific Officer at Otonomy, Inc., from 2009 to 2016. Before joining Otonomy, he was President and CEO of Akesis Pharmaceuticals, Inc., a virtual metabolic disorders company, and prior to that spent more than 14 years at Amgen as an executive director in a variety of R&D management positions. Carl also worked as a research scientist at Alkermes Inc. and started his career as a consultant at Arthur D. Little, a management and technology consulting firm where he worked across several industries.

Carl is a scientific fellow of the American Academy of Otolaryngology, and a full member of both the American Association for the Advancement of Science and the Society of Toxicology. He received his B.S. in Chemistry from the University of Detroit and his Ph.D. in Biomedical Sciences/Toxicology from Northeastern University. He was a NIEHS post-doctoral fellow in Molecular Neurotoxicology at the University of California Irvine. Carl is also a co-inventor on numerous patents in the field of drug delivery for otology-related disorders.